Literature DB >> 23674978

Haplotype Based Association Study between t-PA Gene and Essential Hypertension.

Kosuke Saito1, Tomohiro Nakayama, Naoyuki Sato, Yoshiyuki Kaneko, Ichiro Sato, Akihiko Morita, Teruyuki Takahashi, Masayoshi Soma, Ron Usami.   

Abstract

Several previous studies have shown that essential hypertension (EH) is associated with fibrinolysis. Tissue plasminogen activator (t-PA) plays a key role in fibrinolysis. Thus, it is possible that the t-PA gene is a susceptibility gene of EH. However, there have been no reported studies of association between EH and the t-PA gene using single nucleotide polymorphisms (SNPs). The aim of the present haplotype-based case-control study was to investigate whether SNPs in the human t-PA gene are associated with EH. We performed a genetic association study using 3 SNPs (rs7007329, rs8178750, rs4471024). The subjects were 276 EH patients and 283 age-matched normotensive (NT) individuals. There were no significant differences in overall distribution of genotypes or alleles between EH patients and NT subjects. Also, there were no significant differences in the haplotype-based case-control study. The present results do not indicate an association between the t-PA gene and EH.

Entities:  

Keywords:  association study; essential hypertension; genetic; haplotype; single nucleotide polymorphism; tissue plasminogen activator

Year:  2006        PMID: 23674978      PMCID: PMC3614594     

Source DB:  PubMed          Journal:  Int J Biomed Sci        ISSN: 1550-9702


INTRODUCTION

Essential hypertension (EH) is caused by both genetic and environmental factors. It is generally presumed that EH is a multifactorial inheritance disorder involving several susceptibility genes. Thus, it is important to identify susceptibility genes of EH. However, although there have been studies of relationships between several candidate genes and EH, the major susceptibility genes of EH have not been identified (1). It was previously predicted that EH is related to disorders in the coagulation-fibrinolytic balance (2, 3). The blood coagulation and fibrinolysis system is regulated by the interaction of many factors. Tissue plasminogen activator (t-PA), which converts plasminogen to plasmin, plays an important role in plasma circulation (4), and increased levels of t-PA antigen may predict risk of cardiovascular diseases such as myocardial infarction (MI) and thrombotic stroke (5, 6). It has been reported that release of t-PA appears to be associated with activity of the endogenous kininogen/kinin system, which is related to EH (7). Thus, the available evidence suggests that the t-PA gene is associated with EH. However, the relationship between EH and the t-PA gene has not been examined using an association study. The human t-PA gene has been mapped to chromosome 8p12-p11.2. It consists of 14 exons and 13 introns, and spans approximately 32 kb (8). The present haplotype-based case-control study is the first to investigate whether single nucleotide polymorphisms (SNPs) in the human t-PA gene are associated with EH.

METHODS

Subjects

The EH subjects were 276 Japanese patients (mean age, 60.0 ± 5.6 years years) with EH diagnosed according to World Health Organization criteria, which included a sitting systolic blood pressure (SBP) of >160 mmHg and/or diastolic blood pressure (DBP) of >100 mmHg on 3 different occasions during the 2 months following the first medical examination. None of the EH subjects was using antihypertensive medication. Patients diagnosed with secondary hypertension were excluded. The controls were 283 Japanese normotensive (NT) healthy individuals (mean age, 77.9 ± 4.6 years). None of the control subjects had a family history of hypertension, and all had a SBP of <130 mmHg and a DBP of <85 mmHg. A family history of hypertension was defined as prior diagnosis of hypertension in a grandparent, uncle, aunt, parent or sibling. Both groups were recruited from the northern area of Tokyo, Japan. Informed consent was obtained from each subject according to a protocol approved by the Human Studies Committee of Nihon University (9).

Biochemical analysis

Plasma concentrations of total cholesterol and high-density lipoprotein (HDL)-cholesterol and serum concentrations of creatinine and uric acid were measured using the methods of the Clinical Laboratory Department of Nihon University Hospital (10).

Genotyping

Based on information from the National Center for Biotechnology Information (NCBI) SNP database or the Applied Biosystems (Foster City, CA) - Celera Discovery System (CDS) database (http://www.appliedbiosystems.com), we chose SNPs that had a minor allele frequency of >20%. For the genetic association analysis, we selected the following 3 SNPs in the human t-PA gene: rs7007329 (G/C), located at nucleotide (nt) -4360 upstream of the transcription initiation site; rs8178750 (T/C), nt +20324 in intron 6; rs4471024 (G/A), nt +624 downstream of the terminal codon (Figure 1). Genotypes were determined using Assays-on-Demand kits (Applied Biosystems) and TaqMan PCR, as described previously (11).
Figure 1

Organization of the human t-PA gene and location of the SNPs used for the association analysis. Closed black boxes indicate exons, and lines indicate introns.

Organization of the human t-PA gene and location of the SNPs used for the association analysis. Closed black boxes indicate exons, and lines indicate introns.

Haplotype-based case-control analysis

We performed haplotype-based case-control analysis of 4 combinations of the 3 SNPs. The frequency of each haplotype was estimated using the expectation/maximization (EM) algorithm (12, 13). Haplotype and linkage disequilibrium (LD) analyses were performed using the software SNPAlyze version 3.2 (DYNACOM Co., Ltd. Yokohama, Japan), which is available from the website http://www.dynacom.co.jp/products/package/snpalyze/index.html.

Statistical analysis

Data are shown as mean ± SD. Differences in clinical data between the EH and NT groups were assessed using analysis of variance (ANOVA) followed by a Fisher’s protected least significant difference (PLSD) test. Hardy-Weinberg equilibrium was assessed using chi-square analysis. If expected values were small (<2.0), the genotypes with the small expected values were combined (14). The overall distribution of SNP alleles was analyzed using 2 × 2 contingency tables, and differences in distribution of the SNP genotypes between the EH patients and NT controls were assessed using a 2-sided Fisher exact test and multiple logistic regression analysis. Statistical significance was established at p<0.05. The threshold value of the frequencies of the haplotypes included in the analysis was set to 1%. All haplotypes below the threshold value were excluded from the analysis. Overall distribution of haplotypes was analyzed using 2 × m contingency tables, with a p value of <0.05 considered to indicate statistical significance. The p value of each haplotype was determined using chi-square analysis, the permutation method, and SNPAlyze version 3.2 (14). Pair-wise linkage disequilibrium (LD) patterns for the t-PA gene were evaluated using |D’| and r2.

RESULTS

Table 1 shows clinical characteristics of the subjects. There were significant differences in body mass index (BMI), SBP and DBP between EH and NT subjects. Among male subjects, there were significant differences in pulse rate, total cholesterol, smoking habit, uric acid and alcohol consumption between EH and NT subjects. There were no significant differences in creatinine or HDL-cholesterol between EH and NT subjects.
Table 1

Characteristics of study participants

Total
p valueMen
p valueWomen
p value
EHNTEHNTEHNT

Number of subjects2762831801899694
Age (years)51.0 ± 5.651.4 ± 8.60.51750.9 ± 5.851.9 ± 6.70.13851.2 ± 5.250.4 ± 11.50.568
BMI (kg/m2)24.6 ± 3.822.7 ± 3.3<0.00124.7 ± 3.722.9 ± 3.2<0.00124.3 ± 4.122.4 ± 3.40.001
SBP (mmHg)173.9 ± 20.4112.8 ± 10.6<0.001171.8 ± 19.6113.1 ± 10.3<0.001177.8 ± 21.5112.1 ± 11.4<0.001
DBP (mmHg)105.4 ± 13.569.6 ± 8.3<0.001105.6 ± 13.570.3 ± 7.9<0.001105.1 ± 13.568.2 ± 9.0<0.001
Pulse (beats/min)77.7 ± 15.573.8 ± 14.10.00677.6 ± 16.373.3 ± 15.40.02277.9 ± 14.074.8 ± 10.90.142
Creatinine (mg/dl)0.85 ± 0.250.83 ± 0.220.4220.94 ± 0.240.90 ± 0.200.0970.68 ± 0.180.70 ± 0.180.394
Total cholesterol (mg/dl)210.5 ± 36.5200.7 ± 41.60.005204.9 ± 34.5196.4 ± 38.60.033220.3 ± 38.1209.3 ± 46.10.078
HDL cholesterol (mg/dl)57.0 ± 17.756.5 ± 17.40.75353.5 ± 16.854.3 ± 16.00.68663.0 ± 17.561.0 ± 19.30.491
Uric acid (mg/dl)5.7 ± 1.65.4 ± 1.50.1046.2 ± 1.55.8 ± 1.40.0324.7 ± 1.54.6 ± 1.20.677
Alcohol consumption (%)67.760.10.09883.772.20.01737.535.50.801
Smoking (%)54.242.00.01164.752.80.03833.720.60.078

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; EH, essential hypertension; NT, normotension.

Characteristics of study participants BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; EH, essential hypertension; NT, normotension. Table 2 shows the distributions of genotype and allelic frequencies for the 3 SNPs in EH patients and NT subjects. There were no significant differences in genotype or allelic distributions of any of the SNPs between the two groups, for total subjects, male subjects or female subjects.
Table 2

Genotype and allele distributions in EH patients and NT subjects

Total
p valueMen
p valueFemale
p value
Number of participants2762831801899694
VariantsEHNTEHNTEHNT
rs7007329Genotype
G/G20 (0.072)18 (0.064)12 (0.067)11 (0.058)8 (0.083)7 (0.074)
G/C109 (0.395)115 (0.406)71 (0.394)73 (0.386)38 (0.396)42 (0.447)
C/C147 (0.533)150 (0.530)0.90197 (0.539)105 (0.556)0.91950 (0.521)45 (0.479)0.775
Allele
G149 (0.270)151 (0.267)95 (0.264)95 (0.251)54 (0.281)56 (0.298)
C403 (0.730)415 (0.733)0.906265 (0.736)283 (0.749)0.696138 (0.719)132 (0.702)0.721
rs8178750Genotype
T/T3 (0.011)1 (0.004)1 (0.006)0 (0)2 (0.021)1 (0.011)
T/C11 (0.040)10 (0.035)6 (0.033)7 (0.037)5 (0.052)3 (0.032)
C/C262 (0.949)272 (0.961)0.563173 (0.961)182 (0.963)0.58189 (0.927)90 (0.957)0.614
Allele
T17 (0.031)12 (0.021)8 (0.022)7 (0.019)9 (0.047)5 (0.027)
C535 (0.969)554 (0.979)0.313352 (0.978)371 (0.981)0.722183 (0.953)183 (0.973)0.294
rs4471024Genotype
G/G49 (0.177)57 (0.201)29 (0.161)39 (0.207)20 (0.208)18 (0.192)
G/A133 (0.482)130 (0.459)88 (0.489)87 (0.460)45 (0.469)43 (0.457)
A/A94 (0.341)96 (0.339)0.75263 (0.350)63 (0.333)0.53331 (0.323)33 (0.351)0.908
Allele
G231 (0.418)244 (0.431)146 (0.406)165 (0.437)85 (0.443)79 (0.420)
A321 (0.582)322 (0.569)0.670214 (0.594)213 (0.563)0.395107 (0.557)109 (0.580)0.658

EH, essential hypertension; NT, normotension.

Genotype and allele distributions in EH patients and NT subjects EH, essential hypertension; NT, normotension. There were no significant differences in haplotype distributions between EH patients and NT subjects (Table 3).
Table 3

Haplotype distribution analysis using combinations of the 3 SNPs

Combination of SNPsOverall P-value HaplotypeEHNTIndividual chi-squareIndividual P-value Individual

rs7007329/rs8178750/rs44710240.457CCA0.5340.5080.6460.422
GCA0.0270.0431.8610.173
CTA0.0200.0180.0870.768
CCG0.1790.2081.3890.239
GCG0.2410.2230.4260.514
rs7007329/rs81787500.954CC0.7120.7160.0200.887
GC0.2670.2660.0030.957
CT0.0200.0180.0870.768
rs7007329/rs44710240.344CA0.5530.5260.7620.383
GA0.0290.0431.4580.227
CG0.1770.2071.5320.216
GG0.2410.2240.4290.512
rs8178750/rs44710240.735CA0.5580.5510.0550.815
TA0.0240.0180.4930.483
CG0.4180.4310.1910.662

EH, essential hypertension; NT, normotension.

Haplotype distribution analysis using combinations of the 3 SNPs EH, essential hypertension; NT, normotension. Table 4 shows pair-wise linkage disequilibrium (LD) patterns for the t-PA gene. All SNPs were located in 1 haplotype block.
Table 4

Pairwise linkage disequilibrium(LD) of t-PA gene

SNPsrs7007329rs8178750rs4471024

rs7007329|D´|0.34520.7188
r20.00090.2481
rs8178750|D´|0.7197
r20.0085
rs4471024|D´|
r2
|D´|> 0.5|D´|> 0.3
r2 >0.25
Pairwise linkage disequilibrium(LD) of t-PA gene

DISCUSSIONS

In the present study, using haplotype-based case-control analysis and 3 SNPs, we did not find an association between EH and the human t-PA gene. There have been several previous studies of relationships between the fibrinolytic system and EH. The fibrinolytic system consists of many factors, including t-PA and plasminogen activator inhibitor 1 (PAI-1). A study by Keskin et al. suggests that indicators of fibrinolytic activity such as plasma levels of PAI-1 and beta thromboglobulin (BTG) are associated with EH, but they did not find a relationship between EH and plasma levels of t-PA (15). In addition, the function of t-PA is modulated by interaction with other factors such as PAI-1. Jastrzebska et al. studied relationships between t-PA levels and PAI-1 gene polymorphisms in EH and NT subjects. Their comparison of the 4G allele of an insertion/deletion polymorphism in PAI-1 gene carriers (4G/4G homozygotes) revealed that EH patients had significantly higher levels of fibrinogen (p=0.045), PAI-1 (p=0.009), and t-PA (p=0.007) than NT controls (16). Their data indicate that the t-PA gene is associated with atherothrombotic disease, but not EH. In a previous association study using an Alu-repeat polymorphism in the t-PA gene, there were no significant differences between EH and NT subjects (17). The present strategy of haplotype-based case-control analysis is a more effective method of identifying susceptibility genes than case-control analysis using 1 plolymorphism (18, 19). Our previous LD analysis showed that the |D’| and r2 values of the 3 present SNPs were suitable for haplotype-based case-control analysis (20, 21). Moreover, those 3 SNPs are very useful as genetic markers because they have high minor allele frequencies (>20%). In conclusion, the present results do not indicate an association between the t-PA gene and EH.
  20 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  Fibrinolysis factors and lipid composition of the blood in treated and untreated hypertensive patients.

Authors:  S H Donders; F A Lustermans; J W van Wersch
Journal:  Blood Coagul Fibrinolysis       Date:  1992-02       Impact factor: 1.276

3.  An association study in essential hypertension using functional polymorphisms in lymphotoxin-alpha gene.

Authors:  Tomohiro Nakayama; Masayoshi Soma; Naoyuki Sato; Akira Haketa; Kotoko Kosuge; Noriko Aoi; Mikano Sato; Yoichi Izumi; Koichi Matsumoto; Katsuo Kanmatsuse; Shinichiro Kokubun
Journal:  Am J Hypertens       Date:  2004-11       Impact factor: 2.689

4.  Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension.

Authors:  Maria Jastrzebska; Iwona Goracy; Marek Naruszewicz
Journal:  Thromb Res       Date:  2003-06-15       Impact factor: 3.944

Review 5.  Regulation of endothelial cell t-PA synthesis and release.

Authors:  T Kooistra; Y Schrauwen; J Arts; J J Emeis
Journal:  Int J Hematol       Date:  1994-06       Impact factor: 2.490

6.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

7.  A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: possible association with essential hypertension.

Authors:  Tomohiro Nakayama; Masayoshi Soma; Yoshihiro Mizutani; Xu Xinjuan; Junko Honye; Yukie Kaneko; Dolkun Rahmutula; Noriko Aoi; Kotoko Kosuge; Satoshi Saito; Yukio Ozawa; Katsuo Kanmatsuse; Shinichiro Kokubun
Journal:  Hypertens Res       Date:  2002-05       Impact factor: 3.872

8.  Reactive hyperemia and tissue-type plasminogen activator release in hypertensive men.

Authors:  Giulia Dell'Omo; Ferdinando De Negri; Franco Carmassi; Lucia Ruocco; Mario Mariani; Roberto Pedrinelli
Journal:  Blood Coagul Fibrinolysis       Date:  2003-01       Impact factor: 1.276

9.  Haplotype analysis of the prostacyclin synthase gene and essential hypertension.

Authors:  Tomohiro Nakayama; Masayoshi Soma; Akira Haketa; Noriko Aoi; Kotoko Kosuge; Mikano Sato; Katsuo Kanmatsuse; Shinichiro Kokubun
Journal:  Hypertens Res       Date:  2003-07       Impact factor: 3.872

10.  Prospective study of endogenous tissue plasminogen activator and risk of stroke.

Authors:  P M Ridker; C H Hennekens; M J Stampfer; J E Manson; D E Vaughan
Journal:  Lancet       Date:  1994-04-16       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.